文献速递糖尿病肥胖与代谢综合征

十二指肠-空肠旁路套管对肥胖2型糖尿病患者血糖控制的影响:一项Meta分析及体重减轻与激素变化的二次分析

Effect of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Patients With Type 2 Diabetes With Obesity: A Meta-analysis With Secondary Analysis on Weight Loss and Hormonal Changes.
PubMed 文献 · Diabetes Care · 2018-01-01

该Meta分析纳入17项研究,评估十二指肠-空肠旁路套管(DJBL)对肥胖2型糖尿病患者血糖控制的影响。拔除时HbA1c降低1.3%,HOMA-IR降低4.6,体重减轻11.3 kg;与对照相比HbA1c多降低0.9%。DJBL还引起肠道激素变化,提示机制类似Roux-en-Y胃旁路术。研究局限性包括研究间异质性。

要点

  • DJBL拔除时HbA1c降低1.3%,HOMA-IR降低4.6。
  • 与对照相比,DJBL组HbA1c多降低0.9%。
  • 拔除时体重减轻11.3 kg,BMI降低4.1 kg/m2。

核心结论

  • DJBL可改善肥胖2型糖尿病患者的血糖控制和胰岛素抵抗。
  • DJBL似乎还可诱导该人群显著体重减轻。
  • 肠道激素变化提示其机制类似Roux-en-Y胃旁路术。

研究设计与样本

  • 检索MEDLINE、EMBASE和Web of Science截至2017年7月1日的文献,纳入评估DJBL在肥胖2型糖尿病患者中结局的已发表研究,共纳入17项研究。

主要发现

  • 拔除时HbA1c降低1.3%[95%CI 1.0,1.6],HOMA-IR降低4.6[2.9,6.3]。
  • 与对照受试者相比,DJBL受试者HbA1c多降低0.9%[0.5,1.3]。
  • 拔除后6个月,HbA1c仍较基线低0.9%[0.6,1.2]。
  • 拔除时患者体重减轻11.3 kg[10.3,12.2],对应BMI降低4.1 kg/m2[3.4,4.9],总体重减轻18.9%[7.2,30.6],超重体重减轻36.9%[29.2,44.6]。
  • DJBL后GIP降低,而GLP-1、PYY和ghrelin升高。

关键数值与推荐

  • 主要结局为HbA1c和胰岛素抵抗HOMA-IR的变化;次要结局为体重和肠道激素GIP、GLP-1、PYY和ghrelin的变化。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 研究局限性包括研究间异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Duodenal-jejunal bypass liner (DJBL) is an endoscopic device that may mimic small bowel mechanisms of Roux-en-Y gastric bypass (RYGB). Previous studies have demonstrated the efficacy of DJBL at inducing weight loss. We assessed the effect of DJBL on glycemic control in patients with type 2 diabetes (T2D) with obesity. RESEARCH DESIGN AND METHODS: Data sources included MEDLINE, EMBASE, and Web of Science through 1 July 2017. Included were published studies that assessed DJBL outcomes in obese T2D patients. RESULTS: Primary outcomes were change in HbA1c and HOMA of insulin resistance (HOMA-IR). Secondary outcomes were change in weight and gut hormones glucose-dependent insulinotropic peptide (GIP), glucagon-like peptide 1 (GLP-1), peptide YY (PYY), and ghrelin. Seventeen studies were included. At explant, HbA1c decreased by 1.3% [95% CI 1.0, 1.6] and HOMA-IR decreased by 4.6 [2.9, 6.3]. Compared with control subjects, DJBL subjects had greater HbA1c reduction by 0.9% [0.5, 1.3]. Six months after explant, HbA1c remained lower than baseline by 0.9% [0.6, 1.2]. At explant, patients lost 11.3 kg [10.3, 12.2], corresponding to a BMI reduction of 4.1 kg/m2 [3.4, 4.9], total weight loss of 18.9% [7.2, 30.6], and excess weight loss of 36.9% [29.2, 44.6]. The amount of weight loss remained significant at 1 year postexplantation. After DJBL, GIP decreased, whereas GLP-1, PYY, and ghrelin increased. CONCLUSIONS: DJBL improves glycemic control and insulin resistance in T2D patients with obesity. DJBL also appears to induce significant weight loss in this population. Additionally, changes in gut hormones suggest mechanisms similar to RYGB. Study limitations included heterogeneity among studies.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Jirapinyo P, Haas AV, Thompson CC, et al. Effect of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Patients With Type 2 Diabetes With Obesity: A Meta-analysis With Secondary Analysis on Weight Loss and Hormonal Changes. Diabetes Care. 2018. PMID: 29678867. doi:10.2337/dc17-1985

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。